argenex SE $ARGX Shares Newly Bought by Mirae Asset Global Investments Co. Ltd.

Key Points

• Mirae Asset Global Investments opened a position of 8,488 argenx shares in the third quarter, valued at about $8.14 million; institutional investors collectively own 60.32% of the stock.
• Analyst sentiment is broadly positive: 21 analysts rate ARGX a Buy and one a Strong Buy, with an average price target of $1,158.76. UBS upgraded the stock to Buy and raised its target to $1,400.
• argenx reported quarterly EPS of $7.80, beating the $7.44 consensus estimate, and revenue of $1.75 billion. Analysts forecast full-year EPS of $28.63.

Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of argenex SE (NASDAQ:ARGX - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 8,488 shares of the company's stock, valued at approximately $8,139,000.

Several other large investors also recently modified their holdings of the stock. Tidal Investments LLC lifted its stake in argenex by 97.8% in the second quarter. Tidal Investments LLC now owns 2,362 shares of the company's stock valued at $2,191,000 after purchasing an additional 1,168 shares during the last quarter. Squarepoint Ops LLC boosted its stake in argenex by 314.8% in the 2nd quarter. Squarepoint Ops LLC now owns 58,400 shares of the company's stock worth $54,182,000 after purchasing an additional 44,321 shares during the period. Peregrine Capital Management LLC bought a new position in argenex in the 2nd quarter worth about $27,584,000. Optiver Holding B.V. grew its holdings in argenex by 907.0% during the 1st quarter. Optiver Holding B.V. now owns 10,110 shares of the company's stock valued at $7,383,000 after buying an additional 9,106 shares in the last quarter. Finally, BG Investment Services LLC purchased a new position in argenex during the 3rd quarter valued at about $1,397,000. Hedge funds and other institutional investors own 60.32% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ARGX shares. UBS Group upgraded argenex from a "neutral" rating to a "buy" rating and upped their price target for the company from $960.00 to $1,400.00 in a research report on Wednesday, August 26th. Sanford C. Bernstein reaffirmed a "buy" rating on shares of argenex in a research note on Thursday, October 8th. JPMorgan Chase & Co. reaffirmed a "buy" rating on shares of argenex in a research note on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft reaffirmed a "neutral" rating on shares of argenex in a report on Friday, October 9th. Finally, Truist Financial increased their target price on shares of argenex from $1,030.00 to $1,095.00 and gave the stock a "buy" rating in a research note on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $1,158.76.

argenex Stock Performance

NASDAQ ARGX opened at $930.95 on Thursday. argenex SE has a 52-week low of $661.85 and a 52-week high of $1,072.75. The company has a fifty day moving average of $936.34 and a 200-day moving average of $856.24. The company has a market capitalization of $58.54 billion, a P/E ratio of 32.48, a P/E/G ratio of 0.83 and a beta of 0.48.

argenex (NASDAQ:ARGX - Get Free Report) last released its earnings results on Friday, October 23rd. The company reported $7.80 EPS for the quarter, beating analysts' consensus estimates of $7.44 by $0.36. argenex had a return on equity of 47.70% and a net margin of 31.66%. The business had revenue of $1.75 billion for the quarter. As a group, analysts forecast that argenex SE will post 28.63 EPS for the current fiscal year.

argenex Profile

argenx SE NASDAQ: ARGX is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx's lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.